drugset
drugset / Trial / NCT02183337

Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers

NCT02183337 ↗

Phase 1 Completed 20 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Study to investigate the bioavailability of BI 1356 with and without co-administration of pioglitazone and the bioavailability of pioglitazone with and without coadministration of BI 1356

Timeline

Start
2007-02
Primary completion
2007-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 10 mg Oral
Subject Pioglitazone Small molecule 45 mg Oral

Indications

No indication recorded.